Anti-CD33 Monoclonal Antibody BI 836858

Known as: BI 836858 
An engineered, fully human, immunoglobulin (Ig) G1 anti-CD33 monoclonal antibody, with potential antineoplastic activity. Upon administration, anti… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
01220162018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Acute myeloid leukemia (AML) is the second most common type of leukemia in adults. Incidence of AML increases with age with a… (More)
  • figure 1
  • figure 2
Is this relevant?
2018
2018
INTRODUCTION There is long-standing interest in drugs targeting the myeloid differentiation antigen CD33 in acute myeloid… (More)
Is this relevant?
2017
2017
We recently reported that the accumulation of myeloid-derived suppressor cells (MDSC), defined as CD33+HLA-DR−Lin−, has a direct… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Acute myeloid leukemia (AML) is the most common type of acute leukemia, affecting older individuals at a median age of 67 years… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Serial evaluation in patients treated with a 10-day course of decitabine demonstrated higher BI 836858–mediated ADCC at day 28… (More)
Is this relevant?